
Need professional-grade analysis? Visit stockanalysis.com
$395.57B
17.23
33,834
1.48%
WuXi AppTec Co Ltd H (2359) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Diagnostics & Research industry. The stock currently trades at HKD122.90, down 5.90% from the previous close.
Over the past year, 2359 has traded between a low of HKD53.72 and a high of HKD130.60. The stock has gained 128.8% over this period. It is currently 5.9% below its 52-week high.
WuXi AppTec Co Ltd H has a market capitalization of $395.57B, with a price-to-earnings ratio of 17.23 and a dividend yield of 1.48%.
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
Side-by-side comparison against top Healthcare peers.